No controlled human feeding study in the supplied evidence measured platelet reactivity after erythritol exposure; the relevant human crossover (n=20) tested only glucose, GLP-1, PYY and intake . Thrombosis-type findings exist only in zebrafish embryos at 3β7 mg/mL exposure . The correlation question remains untested in humans here.
The hypothesis cannot be confirmed from the supplied evidence. The only controlled human erythritol feeding study provided is a three-way crossover in 20 adults (10 lean, 10 obese) testing sucrose vs erythritol custard meals; its outcomes were glucose, insulin, GLP-1, PYY, satiety ratings, and ad libitum intake β no platelet aggregation, coagulation markers, or thrombosis endpoints were assessed .
Peripheral but relevant signals: zebrafish embryos exposed to erythritol (3β7 mg/mL) showed increased thrombus formation attributed to oxidative stress and inflammation, though this is non-human, high-dose, short-term, and uses developmental embryos . Separately, endogenous erythritol arises from the pentose-phosphate pathway and tracked adiposity gain in young adults (baseline ~60.8 vs 4.1 Β΅M in incident vs stable groups), meaning circulating erythritol is confounded by glucose metabolism itself .
What is missing: randomized human feeding studies with pre/post platelet function testing (e.g., aggregation, flow cytometry), doseβresponse design, dietary glycemic control, and adjustment for baseline cardiometabolic state. Without these, the independence-from-confounders clause is untestable here.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.